Inflammatory cytokines of rheumatoid arthritis (RA) and gastrointestinal cancer (GIC)

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter G. Davidhi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors G. Davidhi1, S. Kullolli2, O. Spahiu3, A. Sallaku4, I. Harizi2, J. Çota5, F. Hoxha6
  • 1Hospital "Ihsan Cabej", Lushnje, Albania, /
  • 2Diagnostic Center "Harrison", Tirana, Albania, /
  • 3University Clinic of Oncology, University Hospital Center Mother Teresa, Tirana, Albania, /
  • 4Service of Oncology, University Hospital Mother Theresa, Tirana, Albania, /
  • 5Harrison Medical Center, Tirana, Albania, /
  • 6Diagnostic Center Unison, Tirana, Albania, /


RA is an inflammatory, autoimmune, systemic disease (with articular and extra-articular involvement). In its pathophysiology are involved a great number of inflammatory cytokines (TNFa, IL1, IL6 ect), patients with RA presents an increased risk for various neoplasm (solid tumors or malignant hemopathy) as a result of inflammatory cytokines (disease activity indicator), medication used for its treatment (DMARDs with small molecules, biologic treatment), and conjunction with other systemic disease which increase probity for neoplasm, ect.